IDEXX Laboratories Aktie
426,97USD | -7,33USD | -1,69% |
WKN: 888210 / ISIN: US45168D1046
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,01 |
The Vanguard Group, Inc. | 11,79 |
Vanguard Group, Inc. (Subfiler) | 11,33 |
State Street Corp. | 4,39 |
BlackRock Fund Advisors | 4,36 |
AllianceBernstein LP | 3,42 |
Fundsmith LLP | 3,24 |
Vanguard Total Stock Market ETF | 3,16 |
Fundsmith Equity Fund | 3,06 |
Geode Capital Management LLC | 2,75 |
Vanguard 500 Index Fund | 2,65 |
BlackRock Institutional Trust Co. NA | 2,40 |
BAMCO, Inc. | 2,34 |
Vanguard Mid Cap Index Fund | 2,12 |
Invesco QQQ Trust | 1,94 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 9 200 | 9 300 | 10 350 | 10 780 | 11 000 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,26 | 0,29 | 0,31 | 0,31 | 0,33 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 635 | 1 013 | 900 | 1 044 | 1 441 |
Summe Anlagevermögen | 1 197 | 1 281 | 1 537 | 1 703 | 1 819 |
Summe Aktiva | 1 832 | 2 295 | 2 437 | 2 747 | 3 260 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 1 655 | 1 662 | 1 747 | 2 138 | 1 775 |
Summe Eigenkapital | 178 | 633 | 690 | 609 | 1 485 |
Summe Passiva | 1 832 | 2 295 | 2 437 | 2 747 | 3 260 |
Adresse
One IDEXX Drive, 04092-2040 Westbrook | |
Telefon | +1 (207) 556-0300 |
Fax | +1 (207) 556-4346 |
Internet | http://www.idexx.com |
Management
Andrew Emerson
Senior Vice President-Corporate |
Asha S. Collins
Independent Director |
Brian Patrick McKeon
Chief Financial Officer, Treasurer & Executive VP |
Bruce L. Claflin
Independent Director |
Daniel M. Junius
Independent Director |
George J. Fennell
Chief Revenue Officer & Senior Vice President |
Irene Chang Britt
Independent Director |
Jeffery Donn Chadbourne
SVP-Commercial Finance & Sales Operations |
John Hart
Senior Vice President-Global Operations |
John Ravis
Investor Relations Contact |
Jonathan J. Mazelsky
President, Chief Executive Officer & Director |
Ken Grady
Chief Information Officer & Senior VP |
Kerry Bennett
SVP, GM-Product, Strategy & Global Reference Labs |
Lawrence D. Kingsley
Non-Executive Chairman |
M. Anne Szostak
Independent Director |
Martin Alexander Smith
Chief Technology Officer & Executive VP |
Michael Erickson
EVP & GM-Point of Care Diagnostics & Telemedicine |
Michael J. Lane
Executive VP, GM-Reference Laboratories & IT |
Michael P. Johnson
Chief Human Resources Officer & Executive VP |
Michael Schreck
EVP, GM-Corporate Accounts & Customer Experience |
Murthy Yerramilli
Senior Vice President-Research & Development |
Sam A. Samad
Independent Director |
Sharon E. Underberg
Secretary, Executive VP & General Counsel |
Sophie V. Vandebroek
Independent Non-Executive Director |
Stuart M. Essig
Independent Director |
Tina Hunt
Executive Vice President-Strategy |